Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are serving as financial advisers to Anthos, while Goodwin Procter LLP is providing legal counsel.
While details of Novartis’ legal representation were not immediately available, the deal underscores its aggressive push in the cardiovascular space—a high-stakes bet that could redefine stroke prevention therapies for years to come.
